Health

SHERIDAN, WYOMING – August 12, 2025 – Eli Lilly’s Phase III results for its next-generation oral GLP-1 therapy, orforglipron, have energized the already competitive obesity drug market, sparking renewed focus on oral weight-loss candidates poised to challenge the injectable-dominated landscape. While Lilly’s data confirmed significant efficacy, industry analysts see room for competitors to gain ground with differentiated mechanisms, dosing advantages, and manufacturing scalability.

SHERIDAN, WYOMING – August 12, 2025 – A wave of safety concerns surrounding adeno-associated virus (AAV) gene therapy has hit the biotechnology sector following multiple patient deaths linked to Sarepta Therapeutics’ platform. While some stakeholders push for urgent refinements to the decades-old technology, others are accelerating work on alternative delivery systems that could reshape the future of genetic medicine.

SHERIDAN, WYOMING – August 12, 2025 – The Department of Health and Human Services (HHS) is facing fresh turbulence after the abrupt dismissal of Gray Delany, the lead implementor of the Make America Healthy Again (MAHA) initiative. The move comes just days after Health Secretary Robert F. Kennedy Jr. terminated 22 mRNA vaccine contracts worth a combined $500 million, triggering intense debate across the biomedical and public health sectors.

SHERIDAN, WYOMING – August 12, 2025 – The U.S. Food and Drug Administration (FDA) has significantly tightened prescribing criteria for bluebird bio’s Skysona, an autologous hematopoietic stem cell-based gene therapy for cerebral adrenoleukodystrophy (CALD). The treatment is now limited to patients with no other therapeutic options or available stem cell donors, following post-marketing findings of a substantially higher incidence of hematologic malignancies than previously reported.

SHERIDAN, WYOMING – August 11, 2025 – The U.S. pharmaceutical sector faces a pivotal moment as recent federal funding cuts to mRNA vaccine programs threaten to slow one of oncology’s most promising frontiers: dendritic cell–based mRNA cancer immunotherapies. With the Department of Health and Human Services ending approximately $500 million in BARDA contracts, industry stakeholders are being called upon to bridge the gap and accelerate clinical translation.

Why mRNA Technology Is Critical for Cancer Immunotherapy

SHERIDAN, WYOMING – August 11, 2025 – Boehringer Ingelheim has secured FDA accelerated approval for its kinase inhibitor Hernexeos (zongertinib), marking the German pharmaceutical company’s first entry into the oncology market in its 140-year history. The approval positions Hernexeos as a new targeted therapy for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD)–activating mutations.

SHERIDAN, WYOMING – August 10, 2025 – Midea Group will make a significant statement at this year’s IFA trade fair, occupying an expansive 2,600-square-meter exhibition space in Hall 5.1. The showcase will feature a diverse portfolio of home appliance and air conditioning solutions, with first-time participation from Küppersbusch Hausgeräte GmbH and its premium brands Küppersbusch and Teka, alongside U.S.-based vacuum cleaner specialist Eureka.

A Unified Platform for Global Brand Visibility

SHERIDAN, WYOMING – August 10, 2025 – The GSMA is preparing to host one of the most significant technology gatherings of the decade as MWC Barcelona returns March 2–5, 2026, celebrating 20 years of convening global connectivity leaders. The milestone event aims to blend two decades of innovation with a forward-looking agenda focused on AI, 5G, enterprise technology, and policy shaping for the next generation of connected solutions.

Two Decades of Industry Collaboration and Impact

SHERIDAN, WYOMING – August 10, 2025 – Eli Lilly is navigating a three-pronged challenge on drug pricing, from regulatory proposals to competitive market dynamics, even as it advances its next-generation oral weight loss candidate, orforglipron. On its second quarter earnings call, the company’s leadership underscored that pricing strategy will remain central to sustaining market share and delivering shareholder value.

Balancing Innovation and Pricing in Obesity Therapeutics

SHERIDAN, WYOMING – August 10, 2025 – Globus Medical, Inc. (NYSE: GMED) reported strong second-quarter 2025 results, achieving record non-GAAP earnings per share and double-digit revenue growth, driven by its U.S. Spine business and strategic integration of Nevro. The performance underscores the company’s operational discipline and its continued push to expand robotic-assisted surgery adoption.

Double-Digit Revenue Growth Across Core Segments